Blogs
Healthcare and Medtech Research Reports
Notizia - Recent Pharma, Healthcare and Biotech Happenings
Genentech remunerates Xencor USD 120 Million for global rights Genentech has remunerated USD 120 million upfront to have global rights to IL-15 cytokine therapeutics in preclinical development at Xencor. Xencor is pursuing IL-15, an immune signaling protein, contemplating that it can stimulate natural killer and cytotoxic T cells without activating the simultaneous temporary increase in regulatory T cell activity associated with the targeting of IL-2. This has intrigued Eli Lilly and Novartis. However, Xencor beliefs its technology can provide better tolerability and a longer half-life. The board member of XPrize upraises USD 100 Million fund ...
Explore More...